Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26541363
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic
Cell Transplantation
#MMPMID26541363
Arora M
; Cutler CS
; Jagasia MH
; Pidala J
; Chai X
; Martin PJ
; Flowers ME
; Inamoto Y
; Chen GL
; Wood WA
; Khera N
; Palmer J
; Duong H
; Arai S
; Mayer S
; Pusic I
; Lee SJ
Biol Blood Marrow Transplant
2016[Mar]; 22
(3
): 449-55
PMID26541363
show ga
Several distinct graft-versus-host disease (GVHD)-related syndromes have been
defined by the National Institutes of Health Consensus Conference. We enrolled a
prospective cohort of 911 hematopoietic cell transplantation (HCT) recipients at
13 centers between March 2011 and May 2014 to evaluate 4 GVHD syndromes: late
acute GVHD (aGVHD), chronic GVHD (cGVHD), bronchiolitis obliterans syndrome, and
cutaneous sclerosis. The median age at HCT was 53.7 years. The majority of
patients received a peripheral blood stem cell transplant (81%) following
nonmyeloablative or reduced-intensity conditioning (55%). Pediatric age group and
use of bone marrow and umbilical cord blood grafts were underrepresented in our
cohort (?11%). The cumulative incidence of late aGVHD (late onset and recurrent)
was 10% at a median of 5.5 months post-HCT, that of cGVHD was 47% at a median of
7.4 months, that of bronchiolitis obliterans was 3% at a median of 12.2 months,
and that of cutaneous sclerosis was 8% at a median onset of 14.0 months. Late
aGVHD and bronchiolitis obliterans had particularly high nonrelapse mortality of
23% and 32%, respectively, by 2 years after diagnosis. The probability of late
aGVHD- and cGVHD-free, relapse-free survival was 38% at 1 year post-HCT and 26%
at 2 years post-HCT. This multicenter prospective study confirms the high rate of
late aGVHD and cGVHD syndromes and supports the need for continuous close
monitoring and development of more effective GVHD treatment strategies to improve
HCT success.
free
free
free
